No Data
No Data
Analysts Offer Insights on Healthcare Companies: 89bio (ETNB), Gain Therapeutics (GANX) and Boston Scientific (BSX)
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Buy Rating for Gain Therapeutics: Innovative AI-Driven Approach and Promising Parkinson's Treatment
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
Express News | HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
Promising Developments in Gain Therapeutics' GT-02287 Drive Buy Rating